Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
MIRCETTE vs AFIRMELLE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination of ethinyl estradiol and desogestrel; estrogen and progestin inhibit gonadotropin release, suppressing ovulation and altering cervical mucus and endometrial receptivity.
Combination oral contraceptive containing ethinyl estradiol and levonorgestrel. Inhibits ovulation by suppressing gonadotropin release (FSH and LH). Also increases cervical mucus viscosity and alters endometrial receptivity.
Prevention of pregnancy,Treatment of moderate acne vulgaris in women aged ≥15 years who have reached menarche and desire contraception
Prevention of pregnancy (FDA-approved)
One tablet daily for 21 days, followed by 7 placebo tablets. Each active tablet contains 0.015 mg ethinyl estradiol and 2 mg chlormadinone acetate. Route: oral.
One tablet (0.1 mg levonorgestrel, 0.02 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days of placebo.
Desogestrel active metabolite etonogestrel: 21-24 hours; ethinyl estradiol: 12-14 hours
Terminal elimination half-life: 12–15 hours. Steady-state achieved within 5 days with Q12H dosing.
Ethinyl estradiol: primarily metabolized via CYP3A4; undergoes first-pass hepatic metabolism, conjugated to sulfate and glucuronide. Desogestrel: prodrug converted to active metabolite etonogestrel via CYP2C9 and CYP3A4; further metabolized by reduction and glucuronidation.
Ethinyl estradiol undergoes first-pass metabolism in gut and liver via CYP3A4, with conjugation to sulfate and glucuronide. Levonorgestrel is metabolized primarily by CYP3A4 to reduced and hydroxylated metabolites, then conjugated.
Urine (50-60% as metabolites, <10% unchanged), feces (30-40% as metabolites)
Renal: 50% as unchanged drug and metabolites; fecal: 40% as metabolites; biliary: ~10% as glucuronide conjugates.
Desogestrel: >95% (albumin, SHBG); ethinyl estradiol: >97% (albumin)
~99% bound to serum albumin and sex hormone-binding globulin.
Desogestrel: 1.5 L/kg; ethinyl estradiol: 2.9 L/kg
2.8 L/kg (apparent Vd), indicating extensive tissue distribution.
Desogestrel (as etonogestrel): 76% (oral); ethinyl estradiol: 55% (oral, variable due to first-pass metabolism)
Oral: ~70% due to first-pass metabolism.
No specific dose adjustment recommended. Use with caution in severe renal impairment due to potential fluid retention.
No dose adjustment required for mild to moderate renal impairment. Not recommended for use in end-stage renal disease.
Contraindicated in severe hepatic disease (Child-Pugh class C) or liver tumors. For mild to moderate impairment (Child-Pugh A-B), use with caution; contraindicated if liver function tests are persistently abnormal.
Contraindicated in acute hepatic disease or severe (Child-Pugh C) hepatic impairment. Use with caution in mild to moderate hepatic impairment; monitor liver function.
Not indicated in prepubertal females. Safety and efficacy in postmenarchal adolescents established based on adult studies.
Not indicated for use before menarche. Post-menarche: same as adult dosing (one tablet daily) based on adult clinical trials.
Contraindicated in postmenopausal women. Not indicated for use in elderly due to lack of efficacy for contraception.
Not indicated for use in postmenopausal women; no specific dose adjustment required in healthy elderly, but limited data available.
Cigarette smoking increases risk of serious cardiovascular events from COC use, especially in women >35 years old who smoke ≥15 cigarettes/day. Do not prescribe to women who smoke and are over 35.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptive use. Risk increases with age (especially in women over 35) and with heavy smoking (15+ cigarettes/day). Women who use combination hormonal contraceptives should be strongly advised not to smoke.
Increased risk of thrombotic disorders (VTE, MI, stroke), especially in smokers and women with hypertension or other risk factors.,Liver disease: discontinue if jaundice or impaired liver function develops.,Elevated blood pressure: monitor and discontinue if hypertension develops.,Gallbladder disease: possible increased risk.,Carbohydrate and lipid metabolism: monitor in diabetic or hyperlipidemic patients.,Headache: may exacerbate migraine or cause new-onset headache.,Uterine bleeding: irregular bleeding may occur.,Depression: discontinue if significant depression occurs.,Ocular effects: discontinue if sudden partial/complete vision loss occurs.,Carcinoma: possible increased risk of breast/cervical cancer, but evidence uncertain.
Thrombotic disorders (venous thromboembolism, stroke, myocardial infarction),Cigarette smoking (increases cardiovascular risk),Hypertension (especially in women with renal disease or migraines),Gallbladder disease,Hepatic neoplasia (benign and malignant),Carbohydrate and lipid metabolism effects,Ocular lesions (retinal thrombosis),Depressed mood or depression,Uterine bleeding irregularities,Reduced efficacy with hepatic enzyme inducers
Thrombophlebitis or thromboembolic disorders (current or history),Cerebrovascular or coronary artery disease (current or history),Known or suspected breast carcinoma,Carcinoma of endometrium or other known/suspected estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior pill use,Hepatic adenoma or carcinoma (current or history),Known or suspected pregnancy,Hypersensitivity to any component,Smoking and age >35 years,Migraine with aura (current or history) in women over 35
Thrombophlebitis or thromboembolic disorders (current or history),Cerebrovascular or coronary artery disease (current or history),Known or suspected breast cancer, endometrial cancer, or other estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior oral contraceptive use,Hepatic adenoma or carcinoma (current or history),Known or suspected pregnancy,Hypersensitivity to any component of the product,Heavy smoking (≥15 cigarettes/day) in women over 35
No significant food interactions known; however, grapefruit juice may increase estrogen levels via CYP3A4 inhibition, though clinical significance is low. Avoid St. John's wort as it induces metabolism of ethinyl estradiol and desogestrel, potentially reducing contraceptive efficacy.
Grapefruit juice may increase ethinyl estradiol levels; avoid large quantities. No significant food restrictions. Administer with food if GI upset occurs.
FDA Pregnancy Category X. Contraindicated in pregnancy. First trimester exposure associated with congenital anomalies (cardiovascular, limb reduction, neural tube defects). Second/third trimester exposure may cause fetal adrenal suppression, virilization of female fetus, and metabolic disturbances.
Pregnancy category X. Contraindicated in pregnancy due to risk of fetal harm. First trimester: exposure associated with congenital anomalies (e.g., cardiovascular, neural tube defects). Second and third trimesters: increased risk of fetal growth restriction, preterm birth, and neonatal respiratory distress. Postnatal: possible long-term developmental effects.
Excreted into breast milk. M/P ratio unknown. Potential for serious adverse effects in nursing infant (adrenal suppression, hormonal imbalance). Contraindicated during breastfeeding per manufacturer.
Contraindicated during breastfeeding. Small amounts of ethinyl estradiol and norethindrone are excreted in breast milk; M/P ratio not well defined. Potential for adverse effects on infant (e.g., jaundice, breast enlargement). May reduce milk production and quality.
No dose adjustments applicable as drug is contraindicated in pregnancy. Pharmacokinetic changes in pregnancy (increased clearance, volume of distribution) would theoretically require dose increase, but use is not recommended.
Contraindicated in pregnancy; no dose adjustment recommended. If exposure occurs, immediate discontinuation is required. No pharmacokinetic data support safe use; avoid use entirely.
Mircette is a monophasic oral contraceptive containing 0.15 mg desogestrel and 0.02 mg ethinyl estradiol. It has a shorter hormone-free interval (2 days of placebo) than traditional 7-day placebo regimens, which may reduce breakthrough ovulation and improve suppression of ovarian activity. Counsel patients that the first 7 days of the initial cycle may require a backup method. Desogestrel has low androgenicity and may improve acne. Use with caution in patients with migraine with aura or increased cardiovascular risk.
Afirmelle (levonorgestrel/ethinyl estradiol) is a combined oral contraceptive. Counsel patients to take at the same time daily to maintain consistent hormone levels. Use back-up contraception if a dose is missed. Monitor for signs of thromboembolism, especially in smokers over 35. Advise that certain antibiotics (e.g., rifampin) and anticonvulsants (e.g., phenytoin) may reduce efficacy. Consider progestin-only pill if contraindications to estrogen exist.
Take one tablet at the same time daily; missed pills increase pregnancy risk.,If you miss a pill, refer to the package insert for instructions; use backup contraception if needed.,Mircette may reduce menstrual bleeding and cramping; do not skip pills during withdrawal bleeding.,Smoking while on this pill increases risk of blood clots, especially in women over 35.,Some antibiotics and anticonvulsants may reduce effectiveness; inform your healthcare provider of all medications.,Do not take if you have a history of blood clots, certain cancers, or liver disease.
Take one pill at the same time every day, even if you don't have sex.,If you miss a pill, follow the instructions in the package insert or ask your healthcare provider.,Use a backup method (like condoms) if you start late or miss pills.,This medication does not protect against HIV or other sexually transmitted infections.,Common side effects include nausea, breast tenderness, and breakthrough bleeding.,Seek medical help if you have symptoms of a blood clot: sudden chest pain, leg swelling, or shortness of breath.,Smoking while on this pill increases your risk of serious cardiovascular events.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about MIRCETTE vs AFIRMELLE, answered by our medical review team.
MIRCETTE is a Oral Contraceptive that works by Combination of ethinyl estradiol and desogestrel; estrogen and progestin inhibit gonadotropin release, suppressing ovulation and altering cervical mucus and endometrial receptivity.. AFIRMELLE is a Combined Oral Contraceptive that works by Combination oral contraceptive containing ethinyl estradiol and levonorgestrel. Inhibits ovulation by suppressing gonadotropin release (FSH and LH). Also increases cervical mucus viscosity and alters endometrial receptivity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between MIRCETTE and AFIRMELLE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of MIRCETTE is: One tablet daily for 21 days, followed by 7 placebo tablets. Each active tablet contains 0.015 mg ethinyl estradiol and 2 mg chlormadinone acetate. Route: oral.. The standard adult dose of AFIRMELLE is: One tablet (0.1 mg levonorgestrel, 0.02 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days of placebo.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between MIRCETTE and AFIRMELLE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. MIRCETTE is classified as Category C. FDA Pregnancy Category X. Contraindicated in pregnancy. First trimester exposure associated with congenital anomalies (cardiovascular, limb reduction, neural tube defects). Second/. AFIRMELLE is classified as Category C. Pregnancy category X. Contraindicated in pregnancy due to risk of fetal harm. First trimester: exposure associated with congenital anomalies (e.g., cardiovascular, neural tube defe. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.